Text size Intellia CEO John Leonard called the results a vindication of the company’s modular approach to Crispr therapies. Courtesy Intellia Therapeutics Patients who got a one-time gene-editin...
Text size Intellia CEO John Leonard called the results a vindication of the company’s modular approach to Crispr therapies. Courtesy Intellia Therapeutics Patients who got a one-time gene-editin...